FDA’s Office of Prescription Drug Promotion (OPDP) held a teleconference with Eli Lilly & Co. about problematic promotional materials for its imaging product Amyvid (florbetapir F 18 injection), then followed up with a “notice of violation” letter even though the company promised to comply.
This description of the phone call is included in the enforcement letter, but in what an FDA spokesman called “a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?